SG10202109919PA - Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction - Google Patents
Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reductionInfo
- Publication number
- SG10202109919PA SG10202109919PA SG10202109919PA SG10202109919PA SG 10202109919P A SG10202109919P A SG 10202109919PA SG 10202109919P A SG10202109919P A SG 10202109919PA SG 10202109919P A SG10202109919P A SG 10202109919PA
- Authority
- SG
- Singapore
- Prior art keywords
- bimatoprost
- prostamides
- prostaglandins
- sustained release
- analogs
- Prior art date
Links
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 title 2
- 229960002470 bimatoprost Drugs 0.000 title 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 title 1
- 150000003180 prostaglandins Chemical class 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361811682P | 2013-04-12 | 2013-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202109919PA true SG10202109919PA (en) | 2021-10-28 |
Family
ID=51686960
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202109919P SG10202109919PA (en) | 2013-04-12 | 2014-04-09 | Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction |
| SG10201701938PA SG10201701938PA (en) | 2013-04-12 | 2014-04-09 | Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201701938PA SG10201701938PA (en) | 2013-04-12 | 2014-04-09 | Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20140308354A1 (enExample) |
| EP (2) | EP3656375A1 (enExample) |
| JP (1) | JP2016520561A (enExample) |
| KR (1) | KR20150141972A (enExample) |
| CN (2) | CN105101962A (enExample) |
| AU (2) | AU2014250937A1 (enExample) |
| BR (1) | BR112015025915A8 (enExample) |
| CA (1) | CA2908731A1 (enExample) |
| CL (1) | CL2015003023A1 (enExample) |
| DK (1) | DK2983663T3 (enExample) |
| ES (1) | ES2785382T3 (enExample) |
| IL (1) | IL242006B (enExample) |
| MX (1) | MX381097B (enExample) |
| MY (1) | MY187802A (enExample) |
| RU (1) | RU2015143859A (enExample) |
| SG (2) | SG10202109919PA (enExample) |
| WO (1) | WO2014169075A1 (enExample) |
| ZA (1) | ZA201507217B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA120775C2 (uk) * | 2015-04-30 | 2020-02-10 | Аллерган, Інк. | Косметичний спосіб та його терапевтичне застосування для зменшення об'єму жирової тканини |
| US11452703B2 (en) * | 2020-05-21 | 2022-09-27 | Peregrine Ophthalmic PTE LTD. | Methods and compositions for reducing adipocyte numbers |
| CN116133663B (zh) * | 2020-07-21 | 2025-10-17 | 阿勒根公司 | 具有高前列腺酰胺负载量的眼内植入物 |
| AU2024258544A1 (en) * | 2023-04-18 | 2025-09-04 | Welfare Concepts Limited | Composition and method for inducing luteolysis |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2218424A (en) * | 1931-05-07 | 1940-10-15 | Teleregister Corp | Transmitter and code translator |
| US4525359A (en) * | 1982-12-10 | 1985-06-25 | Greenway Frank L Iii | Treatment for selective weight control |
| US6124344A (en) * | 1993-12-28 | 2000-09-26 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| AU693698B2 (en) * | 1995-05-18 | 1998-07-02 | Allergan, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylakenyl derivatives as therapeutic agents for the treatment of ocular hypertension |
| JP4705782B2 (ja) | 2002-10-23 | 2011-06-22 | スキャンポ・アーゲー | 肥満の処置のためのプロスタグランジン化合物 |
| CA2508303C (en) * | 2002-12-04 | 2012-10-23 | Santen Pharmaceutical Co., Ltd. | Drug delivery system using subconjunctival depot |
| AU2004308971A1 (en) * | 2003-12-22 | 2005-07-14 | Aventis Pharmaceuticals Inc. | Injectable phosphatidylcholine preparations |
| US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| CA2681668C (en) * | 2006-03-23 | 2014-04-01 | Michael S. Singer | Compositions comprising prostaglandin f2-alpha analogs and methods for reducing body fat |
| GB2443287B (en) * | 2006-10-17 | 2009-05-27 | Lipothera Inc | Methods, compositions and formulations for the treatment of thyroid eye disease |
| US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US9095506B2 (en) * | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| WO2011109384A2 (en) * | 2010-03-02 | 2011-09-09 | Allergan, Inc. | Biodegradable polymers for lowering intraocular pressure |
| EP2595604B1 (en) | 2010-07-21 | 2016-03-30 | Allergan, Inc. | Method of controlling initial drug release of sirna from sustained-release implants |
| US9289413B2 (en) * | 2013-03-15 | 2016-03-22 | Allergan, Inc. | Prostamide-containing intraocular implant |
| UA120775C2 (uk) | 2015-04-30 | 2020-02-10 | Аллерган, Інк. | Косметичний спосіб та його терапевтичне застосування для зменшення об'єму жирової тканини |
-
2014
- 2014-04-09 WO PCT/US2014/033558 patent/WO2014169075A1/en not_active Ceased
- 2014-04-09 ES ES14725582T patent/ES2785382T3/es active Active
- 2014-04-09 RU RU2015143859A patent/RU2015143859A/ru not_active Application Discontinuation
- 2014-04-09 EP EP20152147.3A patent/EP3656375A1/en not_active Withdrawn
- 2014-04-09 MX MX2015014320A patent/MX381097B/es unknown
- 2014-04-09 BR BR112015025915A patent/BR112015025915A8/pt active Search and Examination
- 2014-04-09 AU AU2014250937A patent/AU2014250937A1/en not_active Abandoned
- 2014-04-09 KR KR1020157029970A patent/KR20150141972A/ko not_active Ceased
- 2014-04-09 CN CN201480020790.8A patent/CN105101962A/zh active Pending
- 2014-04-09 US US14/248,898 patent/US20140308354A1/en not_active Abandoned
- 2014-04-09 CN CN201910977574.7A patent/CN110840899A/zh active Pending
- 2014-04-09 MY MYPI2015002531A patent/MY187802A/en unknown
- 2014-04-09 SG SG10202109919P patent/SG10202109919PA/en unknown
- 2014-04-09 JP JP2016507645A patent/JP2016520561A/ja active Pending
- 2014-04-09 CA CA2908731A patent/CA2908731A1/en not_active Abandoned
- 2014-04-09 SG SG10201701938PA patent/SG10201701938PA/en unknown
- 2014-04-09 DK DK14725582.2T patent/DK2983663T3/da active
- 2014-04-09 EP EP14725582.2A patent/EP2983663B1/en active Active
-
2015
- 2015-09-29 ZA ZA2015/07217A patent/ZA201507217B/en unknown
- 2015-10-09 CL CL2015003023A patent/CL2015003023A1/es unknown
- 2015-10-11 IL IL242006A patent/IL242006B/en active IP Right Grant
-
2016
- 2016-04-21 US US15/134,792 patent/US10682361B2/en active Active
-
2019
- 2019-05-08 AU AU2019203214A patent/AU2019203214B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20160339039A1 (en) | 2016-11-24 |
| CA2908731A1 (en) | 2014-10-16 |
| IL242006B (en) | 2020-04-30 |
| RU2015143859A3 (enExample) | 2018-03-05 |
| MX2015014320A (es) | 2015-12-08 |
| ES2785382T3 (es) | 2020-10-06 |
| HK1221406A1 (en) | 2017-06-02 |
| EP3656375A1 (en) | 2020-05-27 |
| WO2014169075A1 (en) | 2014-10-16 |
| US10682361B2 (en) | 2020-06-16 |
| EP2983663B1 (en) | 2020-01-22 |
| DK2983663T3 (da) | 2020-04-20 |
| MY187802A (en) | 2021-10-26 |
| EP2983663A1 (en) | 2016-02-17 |
| AU2019203214A1 (en) | 2019-05-30 |
| US20140308354A1 (en) | 2014-10-16 |
| BR112015025915A2 (pt) | 2017-07-25 |
| CN105101962A (zh) | 2015-11-25 |
| CL2015003023A1 (es) | 2016-06-10 |
| SG10201701938PA (en) | 2017-04-27 |
| AU2014250937A1 (en) | 2015-10-22 |
| CN110840899A (zh) | 2020-02-28 |
| KR20150141972A (ko) | 2015-12-21 |
| MX381097B (es) | 2025-03-12 |
| RU2015143859A (ru) | 2017-05-16 |
| NZ712804A (en) | 2021-02-26 |
| BR112015025915A8 (pt) | 2020-01-14 |
| ZA201507217B (en) | 2017-09-27 |
| AU2019203214B2 (en) | 2020-10-29 |
| JP2016520561A (ja) | 2016-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262804A (en) | Antibodies to human pac1 | |
| IL245184B (en) | Prostacyclin compounds, preparations and methods of using them | |
| HUE047688T2 (hu) | Eljárások és intermedierek izomermentes prosztaglandinok elõállítására | |
| HUE043088T2 (hu) | Halikondrin B analógok szintézisében alkalmazható eljárások | |
| GB201418044D0 (en) | Method of combating corynespora | |
| SI3055315T1 (sl) | Tiazolopirimidinoni kot modulatorji aktivnosti receptorjev NMDA | |
| PL2984159T3 (pl) | Wytwarzanie laktylanów bezpośrednio z oleju | |
| GB201317149D0 (en) | Ovulation Determination | |
| GB2516136B (en) | Colenterazine analogs | |
| SG11201507276UA (en) | Improved methods of use for recombinant human secretoglobins | |
| EP2981374A4 (en) | CASTING METHOD | |
| IL242006B (en) | Extended release bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction | |
| ZA201507507B (en) | Method for scheduling ovulation | |
| EP2970319A4 (en) | 6-ACETYLMORPHINE ANALOGUE AND METHOD FOR THE SYNTHESIS AND USE | |
| EP2971839A4 (en) | TIGHTENED BRAKE PAD | |
| IL249632B (en) | Asymmetric metal-catalyzed 1,4-conjugation addition of vinylboron compounds to 2-converted-4-ok-cyclopent-2-en-1-ones to obtain prostaglandins and prostaglandin analogs | |
| EP2692360A4 (en) | FATTY EMULSION CONTAINING PROSTAGLANDIN | |
| IL245018A0 (en) | Synthetic intermediate of mexacalcitol, method for its preparation and use | |
| GB201319445D0 (en) | Self-assembly of nanotubes | |
| GB2516028B8 (en) | Improved structure of shoe | |
| SG11201604136PA (en) | Improved formulations for virosomes | |
| GB201314407D0 (en) | Vancomycin analogs | |
| GB201319728D0 (en) | TOAD - Temporary Occlusion of Artery Device | |
| GB201317977D0 (en) | Global Pollination across Human Civilisation infrastructure | |
| GB201321883D0 (en) | Techno pony |